FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004344579> ?p ?o ?g. }

• W2004344579 endingPage "677" @default.
• W2004344579 startingPage "666" @default.
• W2004344579 abstract "Objective:To compare healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus (T2DM) in the United States newly initiating exenatide once weekly (QW) or liraglutide.Methods:This retrospective cohort study used US administrative claims data to study patients with T2DM initiating exenatide QW or liraglutide (initiated therapy = index therapy). Patients were included if they had T2DM, were glucagon-like peptide-1 receptor agonist (GLP-1RA) naïve, initiated exenatide QW or liraglutide from 1 February 2012 to 1 October 2012 (date of initiation = index), were ≥18 years at index, and had continuous enrollment for 12 months before (baseline) to 6 months after index (follow-up). Study outcomes were overall and diabetes-specific healthcare utilization and costs. Multivariable regressions compared the study outcomes between exenatide QW and liraglutide, adjusting for potential confounders. Sensitivity analyses were performed to assess liraglutide by dose (1.2 mg/1.8 mg).Results:The study sample included 9106 liraglutide (4188, 1.2 mg; 4918, 1.8 mg) patients and 2445 exenatide QW patients. In multivariable-adjusted analyses, compared with liraglutide patients, exenatide QW patients had statistically significantly lower odds of overall inpatient admissions (odds ratio [OR] = 0.80, p = 0.046) and diabetes-specific (OR = 0.83, p = 0.026) inpatient admissions, similar overall total costs ($7833 exenatide QW, $8296 liraglutide, p = 0.069) and diabetes-specific total costs ($3610 exenatide QW, $3736 liraglutide, p = 0.298), and statistically significantly lower overall medical costs ($3939 exenatide QW, $4652 liraglutide, p = 0.008) and diabetes-specific medical costs ($1161 exenatide QW, $1469 liraglutide, p = 0.007). Sensitivity analyses assessing liraglutide by dose were directionally consistent. Unadjusted exploratory analyses showed that exenatide QW patients obtained a greater median number of days supplied for their GLP-1RA during follow-up (141 days) than liraglutide patients (124 days).Conclusions:In this 6 month follow-up study, patients receiving exenatide QW had similar total healthcare costs but lower odds of inpatient admission and lower medical costs compared with patients receiving liraglutide." @default.
• W2004344579 created "2016-06-24" @default.
• W2004344579 creator A5000564527 @default.
• W2004344579 creator A5007314209 @default.
• W2004344579 creator A5018579603 @default.
• W2004344579 creator A5067868620 @default.
• W2004344579 creator A5084889915 @default.
• W2004344579 creator A5089346349 @default.
• W2004344579 date "2015-05-06" @default.
• W2004344579 modified "2023-09-26" @default.
• W2004344579 title "Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States" @default.
• W2004344579 cites W125399422 @default.
• W2004344579 cites W1967813980 @default.
• W2004344579 cites W1978047113 @default.
• W2004344579 cites W1993187958 @default.
• W2004344579 cites W2016363498 @default.
• W2004344579 cites W2019499897 @default.
• W2004344579 cites W2028371970 @default.
• W2004344579 cites W2059678666 @default.
• W2004344579 cites W2092039851 @default.
• W2004344579 cites W2097225387 @default.
• W2004344579 cites W2102368961 @default.
• W2004344579 cites W2115977452 @default.
• W2004344579 cites W2124870273 @default.
• W2004344579 cites W2136225651 @default.
• W2004344579 cites W2136726633 @default.
• W2004344579 cites W2152984355 @default.
• W2004344579 cites W2155441883 @default.
• W2004344579 cites W2156108549 @default.
• W2004344579 cites W4229629337 @default.
• W2004344579 cites W4242364069 @default.
• W2004344579 doi "https://doi.org/10.3111/13696998.2015.1039539" @default.
• W2004344579 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25867133" @default.
• W2004344579 hasPublicationYear "2015" @default.
• W2004344579 type Work @default.
• W2004344579 sameAs 2004344579 @default.
• W2004344579 citedByCount "4" @default.
• W2004344579 countsByYear W20043445792016 @default.
• W2004344579 countsByYear W20043445792017 @default.
• W2004344579 countsByYear W20043445792021 @default.
• W2004344579 crossrefType "journal-article" @default.
• W2004344579 hasAuthorship W2004344579A5000564527 @default.
• W2004344579 hasAuthorship W2004344579A5007314209 @default.
• W2004344579 hasAuthorship W2004344579A5018579603 @default.
• W2004344579 hasAuthorship W2004344579A5067868620 @default.
• W2004344579 hasAuthorship W2004344579A5084889915 @default.
• W2004344579 hasAuthorship W2004344579A5089346349 @default.
• W2004344579 hasBestOaLocation W20043445791 @default.
• W2004344579 hasConcept C126322002 @default.
• W2004344579 hasConcept C134018914 @default.
• W2004344579 hasConcept C156957248 @default.
• W2004344579 hasConcept C167135981 @default.
• W2004344579 hasConcept C2777180221 @default.
• W2004344579 hasConcept C2780533449 @default.
• W2004344579 hasConcept C2781308992 @default.
• W2004344579 hasConcept C555293320 @default.
• W2004344579 hasConcept C71924100 @default.
• W2004344579 hasConceptScore W2004344579C126322002 @default.
• W2004344579 hasConceptScore W2004344579C134018914 @default.
• W2004344579 hasConceptScore W2004344579C156957248 @default.
• W2004344579 hasConceptScore W2004344579C167135981 @default.
• W2004344579 hasConceptScore W2004344579C2777180221 @default.
• W2004344579 hasConceptScore W2004344579C2780533449 @default.
• W2004344579 hasConceptScore W2004344579C2781308992 @default.
• W2004344579 hasConceptScore W2004344579C555293320 @default.
• W2004344579 hasConceptScore W2004344579C71924100 @default.
• W2004344579 hasIssue "9" @default.
• W2004344579 hasLocation W20043445791 @default.
• W2004344579 hasLocation W20043445792 @default.
• W2004344579 hasOpenAccess W2004344579 @default.
• W2004344579 hasPrimaryLocation W20043445791 @default.
• W2004344579 hasRelatedWork W1969181381 @default.
• W2004344579 hasRelatedWork W1994806180 @default.
• W2004344579 hasRelatedWork W2145323626 @default.
• W2004344579 hasRelatedWork W2152984355 @default.
• W2004344579 hasRelatedWork W2165395968 @default.
• W2004344579 hasRelatedWork W2404759430 @default.
• W2004344579 hasRelatedWork W2418730221 @default.
• W2004344579 hasRelatedWork W2490399744 @default.
• W2004344579 hasRelatedWork W2592545469 @default.
• W2004344579 hasRelatedWork W2913046323 @default.
• W2004344579 hasVolume "18" @default.
• W2004344579 isParatext "false" @default.
• W2004344579 isRetracted "false" @default.
• W2004344579 magId "2004344579" @default.
• W2004344579 workType "article" @default.